Play Earnings CallPlay Earnings Call
COMPASS Pathways plc (CMPS) Discusses Clinical Trial Plans for PTSD and Commercial Preparations for Treatment-Resistant Depression January 7, 2026 10:00 AM EST
Company Participants
Stephen Schultz – Senior Vice President of Investor Relations
Kabir Nath – CEO & Director
Guy Goodwin – Chief Medical Officer
Michael Gold – Chief Research & Development Officer
Steve Levine – Chief Patient Officer
Lori Englebert – Chief Commercial Officer
Conference Call Participants
Gary Small
Geoffrey Grammer
Myriam Barthes – Journey Clinical, Inc.
Dimitri Cavathas
Ritu Baral – TD Cowen, Research Division
Paul Matteis – Stifel, Nicolaus & Company, Incorporated, Research Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Division
Leonid Timashev – RBC Capital Markets, Research Division
Judah Frommer – Morgan Stanley, Research Division
Jay Olson – Oppenheimer & Co. Inc., Research Division
Patrick Trucchio – H.C. Wainwright & Co, LLC, Research Division
Thomas Shrader – BTIG, LLC, Research Division
Imogen Mansfield – Cantor Fitzgerald & Co., Research Division
Sumant Kulkarni – Canaccord Genuity Corp., Research Division
Conversation
Operator
Good day, ladies and gentlemen, and welcome to this COMPASS Pathways update webinar. [Operator Instructions] As a reminder, this call is being recorded.
I would now like to introduce your host for today’s call, Stephen Schultz. You may begin.
Stephen Schultz
Senior Vice President of Investor Relations
Welcome all of you, and thank you for joining us today for this webinar. My name is Steve Schultz, Senior Vice President of Investor Relations at COMPASS Pathways. The call is being recorded and will be available for 30 days — I’m sorry, the call is being recorded and will be available on the COMPASS Pathways Investor Relations website shortly after the conclusion of the call and will be available for a period of 30 days.
Before we begin, let me remind everyone that during the call today, the team will be making statements about future plans and prospects that constitute forward-looking statements. Each forward-looking statement
